CereVasc Receives FDA IDE Approval to Evaluate eShunt Technology for Alzheimer's Disease
CereVasc has received FDA Investigational Device Exemption (IDE) approval to evaluate its eShunt® System in patients with early symptomatic Alzheimer’s disease. The approval allows the company to investigate a minimally invasive approach that aims to support the brain’s natural clearance of neurotoxins associated with the condition.
The eShunt System is an endovascular shunt designed to divert cerebrospinal fluid (CSF) from the brain to the venous system. The technology uses a minimally invasive transvenous-transdural approach, avoiding the need for conventional open brain surgery.
CSF circulates around the brain and spinal cord, helping protect the central nervous system and remove waste products. CereVasc aims to investigate whether increasing CSF diversion and circulation could support the removal of substances associated with Alzheimer’s disease.
The clinical study will evaluate whether this approach can improve the brain’s natural waste-clearance pathways in people with early symptomatic Alzheimer’s disease. The research will also provide information on the safety and feasibility of using CSF diversion as a potential treatment strategy.
CereVasc is also evaluating the eShunt System for normal pressure hydrocephalus (NPH), a condition involving abnormal accumulation of cerebrospinal fluid. The company has completed enrolment in its STRIDE pivotal randomised controlled trial for this indication.
The Alzheimer’s disease study will explore a different application of CSF diversion, although the system remains investigational and has not received FDA marketing approval.